← Leaderboards
Calies D Menard-Katcher
University Of Colorado Denver
$1,969,192
Attributed
$2,179,942
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $485.1K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,179,942 · 4
By mechanism
K23$1,021,192 · 1
R01$504,000 · 1
R21$421,500 · 1
R03$233,250 · 1
Top collaborators
- Amanda Brooke Muir2 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Donald Ym Leung$75,548,590
- Sachin Wani$2,810,778
- Natalie J Nokoff$940,746
- Ann Elizabeth Caldwell$769,695
- Joanne Carol Masterson$414,690
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortDeglutitionFibrosisEosinophilic EsophagitisDeglutition DisordersFoodInflammatoryTreatment ResponseChronicChildPhenotypeInflammationAdultEsophagusPatient SubsetsEsophageal StenosisAllergensFutureChildhoodEsophageal DiseasesInnovationBiopsyHistologicPathologic
Grant awards (12)
Comparative study of dupilumab and fluticasone in management of fibrostenotic Eosinophilic Esophagitis; a pilot and feasibility clinical trial.$252,000
R01 · FY2025 · DK · contact PI
Comparative study of dupilumab and fluticasone in management of fibrostenotic Eosinophilic Esophagitis; a pilot and feasibility clinical trial.$252,000
R01 · FY2024 · DK · contact PI
Tissue remodeling in Eosinophilic Esophagitis: Discovery of novel pathways$116,625
R03 · FY2021 · DK · contact PI
Structural and molecular markers for detection and monitoring of pediatric fibrostenotic Eosinophilic Esophagitis$69,120
K23 · FY2021 · DK · contact PI
Structural and molecular markers for detection and monitoring of pediatric fibrostenotic Eosinophilic Esophagitis$189,703
K23 · FY2020 · DK · contact PI
Distensibility and Remodeling as markers of Therapeutic Response in Eosinophilic Esophagitis$178,750
R21 · FY2020 · TR
Tissue remodeling in Eosinophilic Esophagitis: Discovery of novel pathways$116,625
R03 · FY2020 · DK · contact PI
Distensibility and Remodeling as markers of Therapeutic Response in Eosinophilic Esophagitis$242,750
R21 · FY2019 · TR
Structural and molecular markers for detection and monitoring of pediatric fibrostenotic Eosinophilic Esophagitis$189,703
K23 · FY2019 · DK · contact PI
Structural and molecular markers for detection and monitoring of pediatric fibrostenotic Eosinophilic Esophagitis$189,703
K23 · FY2018 · DK · contact PI
Structural and molecular markers for detection and monitoring of pediatric fibrostenotic Eosinophilic Esophagitis$189,703
K23 · FY2017 · DK · contact PI
Structural and molecular markers for detection and monitoring of pediatric fibrostenotic Eosinophilic Esophagitis$193,260
K23 · FY2016 · DK · contact PI